A research team at the University of Barcelona shows how allopurinol may prevent aortic aneurysm in Marfan syndrome, paving the way for new clinical trials.

The authors conclude that ruzinurad demonstrated superior urate-lowering over allopurinol, and showed a well-tolerated safety profile in patients with hyperuricemia associated with primary gout.

The authors conclude that ruzinurad demonstrated superior urate-lowering over allopurinol, and showed a well-tolerated safety profile in patients with hyperuricemia associated with primary gout.

A more liberal transfusion strategy for patients with acute MI and anemia does not improve quality of life when compared with a more restrictive approach, according to an analysis of the MINT trial.

As physicians continue to debate the role of race in clinical algorithms, the unusual history of debates over race-specific anemia diagnosis may be instructive.

Key Takeaways Pelabresib and Rituxan combination showed significant clinical benefits in JAK inhibitor-naive myelofibrosis patients, achieving a 65.9% spleen volume reduction at 24 weeks. The MANIFEST ...

The European Medicines Agency (EMA) has designated allopurinol as the first orphan drug for the treatment of Marfan syndrome, a rare connective tissue disease which as no cure to date.

Luspatercept is approved for anemia without previous ESA use in ESA-naive adult patients with very low- to intermediate-risk MDS who may require red blood cell transfusions. The indication is somewhat ...

A groundbreaking new study introduces an AI-powered smartphone app that noninvasively screens for anemia using a photo of a user's fingernail. The study shows the app provides hemoglobin ...

Mutations in FANCX appear to cause a lethal form of Fanconi anemia, a finding that sheds light on unexplained pregnancy loss and offers new avenues for genetic screening.

Learn more about allopurinol's dosage, including available strengths, forms, and how it’s taken.

The results offer some of the first glimpses into real-world findings of the Janus kinase inhibitor in patients with myelofibrosis (MF) and anemia.